Renal Cancer

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis - Beyond the Abstract January 30, 2025

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis - Beyond the Abstract January 30, 2025

Exploring the Effect of Patient Characteristics on the Association Between Warm Ischemia Time and the Risk of Postoperative Acute Kidney Injury after Partial Nephrectomy - Beyond the Abstract January 27, 2025

Adverse Events after Nivolumab and Ipilimumab Combined Immunotherapy in Advanced Renal Cell Carcinoma: A Multicentre Experience in Poland - Beyond the Abstract January 15, 2025

Surgical Experience and Functional Outcomes after Laparoscopic and Robot-Assisted Partial Nephrectomy: Results from a Multi-Institutional Collaboration - Beyond the Abstract January 7, 2025

Impact of Tumor Volume and Other Factors on Renal Function After Partial Nephrectomy - Beyond the Abstract December 19, 2024

Stereotactic Body Radiotherapy (SBRT) for the Treatment of Primary Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis - Beyond the Abstract December 17, 2024

Differences in Mutations Across Tumour Sizes in Clear-Cell Renal Cell Carcinoma - Beyond the Abstract October 21, 2024

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) - Beyond the Abstract October 15, 2024

Diagnostic Accuracy and Safety of Renal Tumour Biopsy in Patients with Small Renal Masses and Its Impact on Treatment Decisions - Beyond the Abstract October 14, 2024

A Genetic Basis for Sex Differences in Xp11 Translocation Renal Cell Carcinoma - Beyond the Abstract September 11, 2024

International Multicenter Real-World REGistry for Patients with Metastatic renAL Cell Carcinoma - Meet-URO 33 Study (REGAL Study) - Beyond the Abstract September 6, 2024

Treatment-Free Survival and Partitioned Survival Analysis of Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab Versus Sunitinib: 5-Year Update of CheckMate 214 - Beyond the Abstract August 29, 2024

Prognostic Significance of Inflammatory Markers in Patients with Advanced Renal Cell Carcinoma Receiving Nivolumab plus Ipilimumab - Beyond the Abstract August 23, 2024

Long-Term Responders to Nivolumab in Previously Treated Advanced Renal Cell Carcinoma: A Sub-Analysis of Meet-URO15 Study - Beyond the Abstract August 22, 2024

The Current Application and Future Potential of Artificial Intelligence in Renal Cancer - Beyond the Abstract August 8, 2024

Prognostic Significance of Absolute Lymphocyte Count in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Combination Immunotherapies - Beyond the Abstract August 6, 2024

Delphi Consensus on Stereotactic Ablative Radiotherapy for Oligometastatic and Oligoprogressive Renal Cell Carcinoma-A European Society for Radiotherapy and Oncology Study Endorsed by the European Association of Urology - Beyond the Abstract July 23, 2024

Effect of Treatment of Residual Disease after Immunotherapy-Based Combinations on Complete Response Rate of Patients with Metastatic Renal Cell Carcinomas - Beyond the Abstract July 22, 2024

Avoiding "Needless" Nephrectomy: What Is the Role of Small Renal Mass Biopsy in 2024? - Beyond the Abstract July 2, 2024

Page 1 of 17